Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADILNASDAQ:RGLSNASDAQ:SLRXNASDAQ:TLGTNASDAQ:UMRX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADILAdial Pharmaceuticals$1.73+1.2%$1.70$0.77▼$14.00$6.93M1.487.90 million shs139,362 shsRGLSRegulus Therapeutics$2.27+2.3%$2.18$1.08▼$3.79$145.33M1.57335,678 shs97,798 shsSLRXSalarius Pharmaceuticals$0.50-2.0%$0.56$0.43▼$2.31$2.43M1.0142,854 shs3,710 shsTLGTTeligent$0.03$0.17▼$1.60N/AN/AN/A6,460 shsUMRXCogent Biosciences$6.54-6.0%$10.50$0.29▼$3.72$277.75M3.931.22 million shs1.78 million shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADILAdial Pharmaceuticals+1.17%-20.28%+26.74%+36.76%-79.65%RGLSRegulus Therapeutics+2.25%+2.25%-20.21%+80.16%+68.15%SLRXSalarius Pharmaceuticals-1.77%+0.42%+1.84%-9.27%-69.39%TLGTTeligent0.00%0.00%0.00%0.00%0.00%UMRXCogent Biosciences0.00%-1.06%+12.08%+47.63%-39.33%The "Smart Money" Is Ready for May 1st Are You? (Ad)Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. One Former Wall St. Trader Explains Why…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADILAdial Pharmaceuticals0.1436 of 5 stars0.02.00.00.01.90.80.6RGLSRegulus Therapeutics2.4282 of 5 stars4.42.00.00.02.01.70.0SLRXSalarius PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATLGTTeligentN/AN/AN/AN/AN/AN/AN/AN/AUMRXCogent BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADILAdial PharmaceuticalsN/AN/AN/AN/ARGLSRegulus Therapeutics2.80Moderate Buy$7.25219.38% UpsideSLRXSalarius Pharmaceuticals2.00HoldN/AN/ATLGTTeligentN/AN/AN/AN/AUMRXCogent BiosciencesN/AN/AN/AN/ACurrent Analyst RatingsLatest ADIL, RGLS, SLRX, UMRX, and TLGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2024RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/19/2024RGLSRegulus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $11.003/18/2024RGLSRegulus TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/18/2024RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/18/2024RGLSRegulus TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$6.003/13/2024RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$2.00 ➝ $3.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADILAdial PharmaceuticalsN/AN/AN/AN/A$2.46 per shareN/ARGLSRegulus TherapeuticsN/AN/AN/AN/A$1.05 per shareN/ASLRXSalarius Pharmaceuticals$1.84M1.30N/AN/A$1.34 per share0.37TLGTTeligentN/AN/AN/AN/AN/AN/AUMRXCogent Biosciences$22.50M12.34N/AN/A$1.04 per share6.29Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADILAdial Pharmaceuticals-$5.12M-$5.72N/AN/AN/AN/A-250.52%-183.24%5/10/2024 (Estimated)RGLSRegulus Therapeutics-$30.04M-$1.59N/AN/AN/AN/A-109.21%-80.55%5/9/2024 (Estimated)SLRXSalarius Pharmaceuticals-$12.54M-$4.53N/AN/AN/AN/A-197.96%-135.23%5/9/2024 (Estimated)TLGTTeligentN/AN/A0.00N/AN/AN/AN/AN/AN/AUMRXCogent Biosciences-$31.83M-$1.04N/AN/AN/A-96.84%-87.78%-52.14%N/ALatest ADIL, RGLS, SLRX, UMRX, and TLGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/22/2024Q4 2023SLRXSalarius Pharmaceuticals-$1.01-$0.22+$0.79-$0.22N/AN/A3/21/2024Q4 2023RGLSRegulus Therapeutics-$0.40-$0.40N/A-$0.40N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADILAdial PharmaceuticalsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/ASLRXSalarius PharmaceuticalsN/AN/AN/AN/AN/ATLGTTeligentN/AN/AN/AN/AN/AUMRXCogent BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADILAdial PharmaceuticalsN/A4.904.90RGLSRegulus TherapeuticsN/A3.313.31SLRXSalarius PharmaceuticalsN/A5.025.02TLGTTeligentN/AN/AN/AUMRXCogent Biosciences0.182.902.90OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADILAdial Pharmaceuticals16.41%RGLSRegulus Therapeutics92.38%SLRXSalarius Pharmaceuticals11.88%TLGTTeligentN/AUMRXCogent Biosciences26.39%Insider OwnershipCompanyInsider OwnershipADILAdial Pharmaceuticals14.47%RGLSRegulus Therapeutics8.41%SLRXSalarius Pharmaceuticals5.50%TLGTTeligent0.17%UMRXCogent Biosciences31.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADILAdial Pharmaceuticals44.05 million3.47 millionNo DataRGLSRegulus Therapeutics3065.46 million59.96 millionOptionableSLRXSalarius Pharmaceuticals24.78 million4.51 millionNot OptionableTLGTTeligent2,357N/AN/AOptionableUMRXCogent Biosciences7242.47 millionN/ANot OptionableADIL, RGLS, SLRX, UMRX, and TLGT HeadlinesSourceHeadlineCogent Biosciences Incmoney.usnews.com - April 24 at 4:34 AMAnalysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT)markets.businessinsider.com - February 26 at 5:33 PMAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA)markets.businessinsider.com - February 26 at 8:53 AMCogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Resultsmarkets.businessinsider.com - February 26 at 8:53 AMBuy Rating Affirmed for Cogent Biosciences Ahead of Key Data Presentation on Bezuclastinib with Strong Upside Potentialmarkets.businessinsider.com - February 15 at 8:43 AMCogent Biosciences Stock Soars After $225M Private Placementmarketwatch.com - February 14 at 10:02 AMCogent Biosciences announces oversubscribed $225M private placementmsn.com - February 14 at 10:02 AMBuy Rating on Cogent Biosciences Amid Market Overreaction and Promising Drug Prospectsmarkets.businessinsider.com - February 9 at 2:23 AMCiti starts Cogent Biosciences at buy, cites GI tumor drug potentialmsn.com - February 8 at 4:22 PMBuy Rating Reiterated for Cogent Biosciences as Bezuclastinib Shows Promise in SUMMIT Trialmarkets.businessinsider.com - December 15 at 7:55 PMMaintaining Buy on Cogent Biosciences Amid Anticipation of Differentiating Data for Bezuclastinibmarkets.businessinsider.com - December 13 at 5:33 PMDow Surges 100 Points; Cogent Biosciences Shares Plungemarkets.businessinsider.com - December 11 at 12:21 PMCogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis Treatmentmarkets.businessinsider.com - December 11 at 12:21 PMCogent Reports Positive Data From Phase 2 APEX Trial Of Bezuclastinib In Systemic Mastocytosismarkets.businessinsider.com - December 11 at 10:08 AMCogent slumps after mid-stage data for rare disorder therapymsn.com - December 11 at 10:08 AMPotential Upside for Cogent Biosciences Due to Imminent Data Readout for Bezuclastinib and Underpriced Sharesmarkets.businessinsider.com - November 21 at 9:11 AMPromising Clinical Trials and Strong Financial Position Justify Buy Rating for Cogent Biosciencesmarkets.businessinsider.com - November 14 at 8:40 AMPromising Clinical Trials and Strong Financial Position Support Buy Rating for Cogent Biosciencesmarkets.businessinsider.com - November 4 at 5:21 PMPromising Market Potential for Cogent Biosciences’ Bezuclastinib Spurs Buy Ratingmarkets.businessinsider.com - October 28 at 7:55 AMAnalyst Expectations for Cogent Biosciences's Futurebenzinga.com - August 30 at 8:53 AMCogent Biosciences Is Beginning To Differentiate Its KIT Inhibitormsn.com - August 15 at 5:40 PMLifeSci Capital Remains a Buy on Cogent Biosciences (COGT)markets.businessinsider.com - August 8 at 3:59 PMDoes Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect?msn.com - July 11 at 1:47 PMCogent Biosciences Shares Rise on Fairmount Funds Management's Stake Acquisitionmarketwatch.com - June 13 at 11:04 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAdial PharmaceuticalsNASDAQ:ADILAdial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Regulus TherapeuticsNASDAQ:RGLSRegulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Salarius PharmaceuticalsNASDAQ:SLRXSalarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.TeligentNASDAQ:TLGTTeligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ.Cogent BiosciencesNASDAQ:UMRXCogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.